Glanbia Nutritionals announces launch of high potency collagen tripeptide ingredient
According to the company, Collamet is absorbed four times faster and has 10 times the efficacy of traditional collagen peptides. The ingredient will initially be offered in the North American market.
Image courtesy of Glanbia Nutrition
Glanbia Nutritionals (Chicago, IL) has introduced a collagen tripeptide ingredient called Collameta that was produced in partnership with Jellice Co. According to the company, Collamet is absorbed four times faster and has 10 times the efficacy of traditional collagen peptides. The ingredient will initially be offered in the North American market.
“We are excited to bring Collameta to market because it provides a much higher percentage of bioactive tripeptide than other tripeptides on the market,” said Rachel Schreck, associate strategic product manager at Glanbia Nutritionals, in a press release. “Formulating with collagen has been a challenge because standard collagen peptides are too big to be absorbed directly, resulting in a larger dose and limitations on certain applications. Collameta is a unique collagen tripeptide with a small molecular weight and high potency allowing for a much smaller dose, just one-tenth of a traditional collagen peptide dose, reducing overage issues and making it possible to add it to a wide variety of applications including ready-to-drink beverages, powder drink mixes, gummies, tablets, capsules, gels, and bars.”
According to the company’s press release, hydrolyzed collagen tripeptide has a small molecular weight of ~300 Da, allowing it to be absorbed directly into the bloodstream four times faster. Compared to other tripeptides, it also contains 50% more bioactive tripeptide, says Glanbia. The dose required is about 500 mg to 1 g per day. The ingredient has been shown in research to support skin, joint, and bone health.
